What are you talking about? We never left the game ace. Regarding ODD..... you're writing things I already know. Get in before the next earnings report. Hope for a dip to $37. Up 100%+ Options not your cup of tea? 100% winners aside. ACN---> $346 Hey Stoney... who's your daddy?
04:06 PM ET 03/25/2024 Nkarta (NKTX) stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its non-Hodgkin lymphoma treatment. prescription to succeed in the market may make your head spin. On this episode of "Industry Insights," we'll discuss what factors to consider with biotech stocks. We also examine how FDA approvals influence sector performance over the long term."> X The company unveiled data from five patients in a Securities and Exchange Commission filing. Its cancer treatment, dubbed NKX019, uses donor immune cells. Scientists then teach those cells to find and destroy specific problematic cells. In this case, those are CD19 cells. After three months, the five patients no longer had any CD19 cells in their blood. Also promisingly, this type of cancer typically arises from immune cells known as B cells. These cells normalized after three months. One patients showed normal B cells after a year. Leerink Partners analyst Daina Graybosch says the results prove the benefit for NKX019, which the company is also testing in patients with lupus nephritis. On Friday, Nkarta stock took a bath after the firm refocused its priorities to NKX019, deemphasizing an acute myeloid leukemia treatment that showed unpromising results. Nkarta stock soared 17.6% to 10.49. Nkarta Stock: Could Autoimmune Diseases Be Next? There's early evidence that CAR-T drugs — the class to which NKX019 belongs — could work in patients with autoimmune diseases. "Caveats include the small sample size and indirect signal, which assumes the oncology findings translate to autoimmune diseases and these pharmacodynamics/pharmacokinetics markers correlate with clinical benefit," Leerink's Graybosch said in a report. Still, she has an outperform rating on Nkarta stock. Shares bounded back over their 50-day moving average on Monday, reversing the Friday downfall, according to MarketSurge.com. Nkarta stock has a perfect IBD Digital Relative Strength Rating of 99.
NKTX Nkarta, Inc. $10.81-0.28 (-2.48%)4:00 PM 03/28/24 NASDAQ | $USD | Post-Market: $11.29 +0.48 (+4.44%) 7:50 PM
THE POOL COVER IS OFF!!! // A SURE SIGN OF SPRING. I forgot to bring the large container out so they wrapped and left the cover. Very heavy. Hummmm. This will be my first real test of the hernia surgery...
The market is closed today so I put together a 4 way parlay NBA bet. Hit me up if you want it. I would like to make the next thread equal parts sports gambling and stock investing. That would really separate us and get us a lot of pub. It's always good to be the first in anything.
I don't know if any readers out there are into sports gambling or not. $1.19------> $1.31 SLOW AND STEADY 3% A DAY EVERY DAY!!! LLAPTerran Orbital Corporation $1.31 0.05(+3.97%)4:00 PM 03/28/24 NYSE |$USD |Post-Market:$1.35+0.04(+3.05%)7:59 PM
VAN REGARDING ODDITY TECH LET ME GIVE YOU AN EXIT NUMBER: $41.50 <----- YOU HAVE A DOUBLE TOP AT $48 AND A HUGE DOWN SLOPE DUE TO THAT MASSIVE INSIDER SELL- THAT REALLY RUINED THINGS.. IT IS IN A DOWNTREND AND REALLY FOR ME I'D TIGHTEN THAT STOP UP TO $42.50 BECAUSE ONCE YOU LOSE $43 IT'S GOING DOWN. CERTAINLY A GOOD AMOUNT OF CAUTION IS WARRANTED. GOOD LUCK!
UPDATE- EVERYBODY LOVING EL!!! $134------> $154 EL The Estée Lauder Companies Inc. 32.08K followers $154.159.11(+6.28%)4:00 PM 03/28/24<----- UP 6% HE'S DONE IT AGAIN!! CONSIDERING SELLING NEXT WEEK... COULD EL BECOME CONSECUTIVE STOCK WINNER NO 35 STAY TUNED CHILDREN. AND STAY TUNED IN! ~SI